TrakCel is proud to sponsor the inaugural Patient-to-Patient Supply for Cell Immunotherapies Summit taking place across October 29th-30th 2020.
Join the Cell and Gene Therapy community as TrakCel Chief Product Officer, Debra Susarchick delivers a keynote detailing the path to commercialisation for cell therapy products.
Mind the Gap: Clinical study to Commercial Success
This will include:
- Setting up operational skeleton during clinical trials.
- Lessons learnt by implementing solutions across US and Europe
- Scaling up this infrastructure to support Commercialization – Challenges and strategies
- Blueprint of commercial portal and related topics including – FDA/EMA review, integrations etc.
Establish Best Practices in Patient-Centric Supply Chains for Cell Immunotherapy
As an increasing number of candidates enter the clinic and promise to be a mainstay in the future of cancer treatment, cell therapies pose unique supply chain challenges.
At the inaugural Patient-to-Patient Supply for Cell Immunotherapies Summit, this community will share their expertise and propose best practice for seamless vein-to-vein delivery at the clinical and commercial scale.
From time and temperature sensitivity, to patient-facing service and integrated platforms, a seamless vein-to-vein supply chain is central in maintaining cell immunotherapy safety and efficacy at scale and maximizing the patient experience.
Achieving Standardization and Operational Excellence in Vein-to-Vein Supply
Hear 16+ real-world case studies led by supply chain, strategic sourcing, apheresis, and technical operations experts from top cell therapy providers. Ensure effective forecasting, risk management, quality assurance and service at scale to meet clinical to commercial demand.
This October virtually meet the industry’s experts from large pharma, biotech, standards agencies and supply chain and logistics service providers. Learn from those already building, adapting, and coordinating the vein-to-vein supply of life changing cell therapies and share your own experience with this community to help establish best practice in cell therapy supply.